Virginia Medical Marijuana Sales Top $15 Million in January
- Virginia’s regulated medical marijuana market generated $15.08 million in sales in January, with dried flower being the largest category at $6.55 million (43% of total sales).
- Concentrates followed closely with $5.03 million in sales, representing about 33% of the monthly market, reflecting strong demand for higher-potency products.
- Infused edibles contributed $2.55 million (17% of sales), while shake and trim products accounted for $920,000 (6%).
- January saw 126,706 medical marijuana transactions, with an average flower price of $10.20 per gram; total sales slightly dipped from December’s $15.6 million but remained above November’s $14.5 million.
Virginia’s regulated medical marijuana market generated $15,084,882 in sales in January, according to newly released data from the Virginia Cannabis Control Authority. Dried flower accounted for the largest share of sales, bringing in $6.55 million for the month. That represents roughly 43% of all medical marijuana revenue in January, maintaining flower’s position as the dominant product category in the state’s program.
Concentrates followed closely behind, totaling $5.03 million in sales, or about 33% of the monthly market. The continued strength of concentrates underscores steady demand for higher-potency and inhalable products among registered patients.
Infused edibles generated $2.55 million in January, making up approximately 17% of total sales. Meanwhile, shake and trim products accounted for $920,000, or about 6% of the market.
In total, Virginia recorded 126,706 medical marijuana transactions in January, with an average flower price of $10.20 per gram and a median price of $10.00 per gram, based on year-to-date figures provided by the state.
The $15.08 million in medical cannabis sales in January is a slight dip from the $15.6 million sold in December, but is above the $14.5 million sold in November.
The January numbers highlight a stable and diversified product mix within Virginia’s medical marijuana program, with flower and concentrates together comprising more than three-quarters of all sales.